Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Viswanadhapalli S, Luo Y, Sareddy GR, Santhamma B, Zhou M, Li M, Ma S, Sonavane R, Pratap UP, Altwegg KA, Li X, Chang A, Chávez-Riveros A, Dileep KV, Zhang KYJ, Pan X, Murali R, Bajda M, Raj GV, Brenner AJ, Manthati V, Rao MK, Tekmal RR, Nair HB, Nickisch KJ, Vadlamudi RK.

Mol Cancer Ther. 2019 Aug;18(8):1341-1354. doi: 10.1158/1535-7163.MCT-18-1258. Epub 2019 May 29.

PMID:
31142661
2.

Utilizing cell line-derived organoids to evaluate the efficacy of a novel LIFR-inhibitor, EC359 in targeting pancreatic tumor stroma.

Hall BR, Cannon A, Thompson C, Santhamma B, Chavez-Riveros A, Bhatia R, Nair HB, Nickisch K, Batra SK, Kumar S.

Genes Cancer. 2019 Feb;10(1-2):1-10. doi: 10.18632/genesandcancer.184.

3.

Esters of levonorgestrel and etonogestrel intended as single, subcutaneous-injection, long-lasting contraceptives.

Meece FA, Ahmed G, Nair H, Santhamma B, Tekmal RR, Zhao C, Pollok NE, Lara J, Shaked Z, Nickisch K.

Steroids. 2018 Sep;137:47-56. doi: 10.1016/j.steroids.2018.07.010. Epub 2018 Aug 4.

4.

Model for Hormonal Emergency Contraception (HEC) in cycling and mated guinea pigs - Studies with the Progesterone Receptor Modulators (PRM) Ulipristal Acetate (UPA/CDB2914) and EC317.

Elger W, Schneider B, Killeen Z, Jewgenow K, Dehnhard M, Friedrich M, Santhamma B, Wedemeyer R, Nickisch K.

J Steroid Biochem Mol Biol. 2018 Oct;183:152-158. doi: 10.1016/j.jsbmb.2018.06.009. Epub 2018 Jun 11.

PMID:
29902513
5.

Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.

Singhal H, Greene ME, Zarnke AL, Laine M, Al Abosy R, Chang YF, Dembo AG, Schoenfelt K, Vadhi R, Qiu X, Rao P, Santhamma B, Nair HB, Nickisch KJ, Long HW, Becker L, Brown M, Greene GL.

Oncotarget. 2017 Sep 28;9(4):4282-4300. doi: 10.18632/oncotarget.21378. eCollection 2018 Jan 12.

6.

Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions.

Elger W, Wyrwa R, Ahmed G, Meece F, Nair HB, Santhamma B, Killeen Z, Schneider B, Meister R, Schubert H, Nickisch K.

J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):305-311. doi: 10.1016/j.jsbmb.2016.07.008. Epub 2016 Jul 20.

PMID:
27449818
7.

Effects of Combination of Estradiol with Selective Progesterone Receptor Modulators (SPRMs) on Human Breast Cancer Cells In Vitro and In Vivo.

Nair HB, Santhamma B, Krishnegowda NK, Dileep KV, Nickisch KJ.

PLoS One. 2016 Mar 24;11(3):e0151182. doi: 10.1371/journal.pone.0151182. eCollection 2016.

8.

A new approach towards the synthesis of drospirenone and steroidal spirolactones.

Santhamma B, Acosta K, Chavez-Riveros A, Nickisch K.

Steroids. 2015 Oct;102:60-4. doi: 10.1016/j.steroids.2015.07.008. Epub 2015 Jul 26.

PMID:
26216206
9.

Synthesis and biological evaluation of 11' imidazolyl antiprogestins and mesoprogestins.

Nickisch K, Elger W, Santhamma B, Garfield R, Killeen Z, Amelkina O, Schneider B, Meister R.

Steroids. 2014 Dec;92:45-55. doi: 10.1016/j.steroids.2014.08.017. Epub 2014 Aug 28.

PMID:
25174783
10.

Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.

Roy SS, Kirma NB, Santhamma B, Tekmal RR, Agyin JK.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1263-71. doi: 10.1007/s00280-014-2463-3. Epub 2014 Apr 12.

11.

Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.

Agyin JK, Santhamma B, Roy SS.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6455-8. doi: 10.1016/j.bmcl.2013.09.043. Epub 2013 Sep 21.

12.

Synthesis of substituted estradiols by the selective aromatization of A-ring of steroidal 19-nor-Δ-4-3-ketones with phenylselenyl halides/hydrogen peroxide.

Santhamma B, Nickisch K.

Steroids. 2013 Jul;78(7):707-10. doi: 10.1016/j.steroids.2013.03.005. Epub 2013 Apr 9.

PMID:
23583602
13.

Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells.

Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A, Agyin JK, Brann D, Sun LZ, Yeh IT, Lee FY, Tekmal RR, Kumar R, Vadlamudi RK.

Cancer Res. 2010 May 15;70(10):4092-101. doi: 10.1158/0008-5472.CAN-09-3834. Epub 2010 May 11.

14.

BU-32: a novel proteasome inhibitor for breast cancer.

Agyin JK, Santhamma B, Nair HB, Roy SS, Tekmal RR.

Breast Cancer Res. 2009;11(5):R74. doi: 10.1186/bcr2411.

15.

Inhibition of monoterpene cyclases by inert analogues of geranyl diphosphate and linalyl diphosphate.

Karp F, Zhao Y, Santhamma B, Assink B, Coates RM, Croteau RB.

Arch Biochem Biophys. 2007 Dec 1;468(1):140-6. Epub 2007 Sep 19.

16.

Structure of limonene synthase, a simple model for terpenoid cyclase catalysis.

Hyatt DC, Youn B, Zhao Y, Santhamma B, Coates RM, Croteau RB, Kang C.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5360-5. Epub 2007 Mar 19.

17.

Reaction of dimethoxycarbene-DMAD zwitterion with 1,2-diones and anhydrides: a novel synthesis of highly substituted dihydrofurans and spirodihydrofurans.

Nair V, Deepthi A, Poonoth M, Santhamma B, Vellalath S, Babu BP, Mohan R, Suresh E.

J Org Chem. 2006 Mar 17;71(6):2313-9.

PMID:
16526779

Supplemental Content

Loading ...
Support Center